Intellia Therapeutics (NTLA) Other Non-Current Assets (2015 - 2026)

Intellia Therapeutics (NTLA) has reported Other Non-Current Assets for 11 consecutive years, with $1.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non-Current Assets fell 64.82% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $1.1 million (down 64.82% YoY), while the FY2025 annual figure was $978000.0, down 74.18% from the prior year.
• Other Non-Current Assets rose to $1.1 million in Q1 2026 per NTLA's latest filing, from $978000.0 in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $4.5 million in Q4 2023 and bottomed at $978000.0 in Q4 2025.
• Historically, Other Non-Current Assets has averaged $3.0 million across 4 years, with a median of $3.2 million in 2024.
• On a YoY basis, Other Non-Current Assets climbed as much as 10.58% in 2025 and fell as far as 74.18% in 2025.
• Intellia Therapeutics' Other Non-Current Assets stood at $4.5 million in 2023, then slipped by 16.16% to $3.8 million in 2024, then sank by 74.18% to $978000.0 in 2025, then gained by 7.57% to $1.1 million in 2026.
• Business Quant data shows NTLA's Other Non-Current Assets at $1.1 million in Q1 2026, $978000.0 in Q4 2025, and $2.9 million in Q3 2025.